SAGE Therapeutics Inc
NASDAQ:SAGE
SAGE Therapeutics Inc
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 471 full-time employees. The company went IPO on 2014-07-18. The firm's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD) in adults. The company has a portfolio of other product candidates with a focus on modulating two central nervous system (CNS) receptor systems, GABA and NMDA. The company targets diseases and disorders of the brain with three focus areas: depression, neurology and neuropsychiatry. Its other advanced product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder (MDD) and PPD. Zuranolone is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. The company has a portfolio of other compounds that target GABAA receptors, including SAGE-324.
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 471 full-time employees. The company went IPO on 2014-07-18. The firm's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD) in adults. The company has a portfolio of other product candidates with a focus on modulating two central nervous system (CNS) receptor systems, GABA and NMDA. The company targets diseases and disorders of the brain with three focus areas: depression, neurology and neuropsychiatry. Its other advanced product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder (MDD) and PPD. Zuranolone is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. The company has a portfolio of other compounds that target GABAA receptors, including SAGE-324.
ZURZUVAE Demand: Shipments of ZURZUVAE to women with postpartum depression grew over 22% quarter-over-quarter, with more than 3,000 women treated in Q1 2025.
Revenue Growth: Collaboration revenue from ZURZUVAE reached $13.8 million in Q1, up 21% from the prior quarter.
Cost Control: R&D expenses dropped by 68% year-over-year and nearly 40% quarter-over-quarter after restructuring, with operating expenses expected to decrease substantially in 2025.
Net Loss Narrowing: Net loss for Q1 2025 was $62.2 million, an improvement from $95.8 million in Q4 2024.
Cash Runway: Sage expects its $424 million cash balance as of March 31, 2025, to fund operations into mid-2027.
Prescriber Trends: About 80% of ZURZUVAE prescriptions now come from OB/GYNs, and 70% of patients receive ZURZUVAE as their first new treatment for PPD.
Strategic Alternatives: The company continues to evaluate a range of strategic options to maximize shareholder value, with no timeline set for completion.
